[Proteins in rheumatology and clinical immunology]

Villiger, ; Peter, M (2011). [Proteins in rheumatology and clinical immunology]. Therapeutische Umschau, 68(11), pp. 603-9. Bern: Huber 10.1024/0040-5930/a000220

Full text not available from this repository. (Request a copy)

Twelve years ago the tumour necrosis factor (TNF) inhibitors revolutionised the therapy of rheumatoid arthritis and other inflammatory rheumatic diseases. Today, in addition to anti-cytokine strategies, immunosuppressive biologicals have been developed that delete B-lymphocytes or inhibit the activation of T-lymphocytes. The spectrum of indications for these protein drugs will broaden substantially in the near future and will likely include also diseases with orphan status (incidence below 1:10'000). Used in the right indication and with knowledge of molecular effects as well as clinical adverse effects these new drugs do not appear to be more dangerous than conventional disease modifying agents (DMARDs).

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Villiger, Peter

ISSN:

0040-5930

Publisher:

Huber

Language:

German

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:23

Last Modified:

17 Mar 2015 21:02

Publisher DOI:

10.1024/0040-5930/a000220

PubMed ID:

22045522

URI:

https://boris.unibe.ch/id/eprint/7950 (FactScience: 213338)

Actions (login required)

Edit item Edit item
Provide Feedback